NewsRx

Search our medical news database

VaxInnate Corporation

VaxInnate's Second Flu Vaccine Candidate Enters Clinical Development; Results Expected in Early 2009

Published in Vaccine Weekly, October 15th, 2008

VaxInnate Corporation, a biotechnology company pioneering breakthrough technology to develop novel seasonal and pandemic influenza vaccines, announced that its second influenza vaccine candidate has entered clinical development.

The Phase I study is expected to yield important information about the safety and immunogenicity - or ability to generate an immune response -- of VaxInnate's hemagglutinin (HA)-flagellin flu vaccine candidate. The study is taking place at the University of Rochester in New York. Results are expected in early 2009.

The HA vaccine candidate links the hemagglutinin (HA) antigen, which has been the key protective component in...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook